United Therapeutics Reports Second Quarter 2008 Financi... (

United Therapeutics Reports Second Quarter 2008 Financial Results

Date:7/31/2008

- Revenues of $68.6 Million, Increase of 32% Over Second Quarter 2007 - EPS of $0.63 per Basic Share, Increase of 125% Over Second Quarter 2007 - Earnings Before Non-Cash Charges of $1.36 per Basic Share, Increase of

56% Over Second Quarter 2007

SILVER SPRING, Md., July 31 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended June 30, 2008.

Total revenues for the second quarter of 2008 were $68.6 million, up 32.3% from $51.8 million for the second quarter of 2007. Net income for the second quarter of 2008 was $14.3 million, or $0.63 per basic share, compared to $5.8 million, or $0.28 per basic share, for the second quarter of 2007. Gross margins from sales were $60.6 million in the second quarter of 2008, compared to $45.8 million in the second quarter of 2007. The increases in revenues and gross margins corresponded to the growth in sales of our lead product, Remodulin. Earnings before non-cash charges, defined as net income before non-cash income taxes, depreciation, amortization, impairment charges and share-based compensation (stock option and share tracking award expense), were $30.7 million for the second quarter of 2008, up 70.3% from $18.0 million for the second quarter of 2007.

"It is gratifying that we are on track to grow our annual revenues in excess of 30% for the sixth consecutive year," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "I am also pleased that, after twelve years of operations, our accumulated deficit has been eliminated and we are now able to report accumulated earnings. These financial accomplishments reflect the decisions of hundreds of
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
2. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
3. United Therapeutics to Announce Second Quarter 2008 Financial Results Before Market Open on Thursday, July 31, 2008
4. Animetrics Inc. Selected to Provide 3D Face Viewer Technology for United States Army Biometric Automated Toolset (BAT)
5. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
6. Genzyme Files Applications for Approval of Mozobil in the United States and Europe
7. Sturgeon and Caviar From Aquaculture: United Food Technologies AG Hands Over Turnkey Plant
8. United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders
9. United Therapeutics Reports First Quarter 2008 Financial Results
10. United Therapeutics to Announce First Quarter 2008 Financial Results Before Market Open on Thursday, May 1, 2008
11. United BioSource Acquires Leading Publication Planning Software and Services Company

Post Your Comments:

United Therapeutics Reports Second Quarter 2008 Financi...( - Revenues of $68.6 Million Increa...)